Combination therapy is not beneficial for certain patients with ovarian cancer
OncLive, MedPage Today highlight UC-led research
OncLive and MedPage Today highlighted research presented by the University of Cincinnati Cancer Center's Thomas Herzog that found a combination therapy of afuresertib and paclitaxel did not lead to better survival outcomes when compared to only treating with paclitaxel in patients with platinum-resistant ovarian cancer.
Afuresertib targets a specific protein called pAKT associated with pathways that support tumor growth, while paclitaxel is a common chemotherapy drug administered to patients with platinum-resistant ovarian cancer.
Herzog presented data from the phase 2 PROFECTA-II/GOG-3044 trial at the 2025 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer. The trial found a median progression-free survival of 4.3 months for patients receiving the combination therapy compared to 4.1 months for those receiving paclitaxel alone.
"Clearly, this was a definitive negative trial for the overall population," said Herzog, MD, a University of Cincinnati Cancer Center member, the Paul and Carolyn Flory Professor in Gynecologic Oncology in the UC College of Medicine and director of UC Health’s Gynecologic Cancer Disease Center. "However, the biomarker data is provocative, but remember, this is hypothesis-generating only, as it's nonanalytic.
“Effective treatments for [platinum-resistant ovarian cancer] remain limited, thus novel agents are needed,” Herzog added. “Biomarker-driven strategies targeting pAKT may refine patient selection and enhance treatment outcomes in [platinum-resistant ovarian cancer]. However, further validation will be required to confirm this biomarker strategy.”
Read the MedPage Today article.
Featured photo at top of Thomas Herzog. Photo provided.
Related Stories
On track: Hoffman Honors Scholar studies public transit
April 2, 2026
Public transit is where Zane Sawyer’s lifelong passion for travel meets his commitment to making an impact. The University of Cincinnati first-year geography major in the College of Arts & Sciences and member of the second cohort of Hoffman Honors Scholars (HHS) has hit the ground running, designing a research project intended to capture both how public transit works and how its users perceive it.
UC design student works with sports greats in co-op
April 2, 2026
Spectrum News profiles UC College of Design, Architecture, Art, and Planning communication design student Jayden Balwally, who had an internship with the Oklahoma City Thunder and worked with the Heisman Trophy Trust and the College Football Playoff.
UC names Suzanne Judd, PhD, as inaugural director of new Center for Public Health
April 2, 2026
Following an extensive national search, the University of Cincinnati College of Medicine has appointed Suzanne E. Judd, PhD, as the inaugural director of its newly established Center for Public Health. Judd, a renowned epidemiologist and interdisciplinary scholar, will lead the center’s mission to transform community health through innovative research, education and strategic advocacy.